Editorial Nuclear Medicine Otolaryngology
Does an antibiotic stewardship programme reduce length of stay in cancer survivors? A retrospective cohort study

Does an antibiotic stewardship programme reduce length of stay in cancer survivors? A retrospective cohort study

Authors

Omar Volkov

Omar Volkov

King Fahad Medical City, Suriname

Leo Osei

Leo Osei

Singapore General Hospital, Lithuania

Corresponding

Published

April 30, 2025

Paper ID

PAP-000307

Status

Published

DOI

10.65712/tmj.test000565

Does an antibiotic stewardship programme reduce length of stay in cancer survivors? A retrospective cohort study

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: The cost of length of stay to health systems is substantial. Methods: Missing data were handled with multiple imputation. Results: Effects were consistent across prespecified subgroups. length of stay occurred in 19% of the intervention group versus 19% of controls. Conclusion: Future work should test an antibiotic stewardship programme in a pragmatic multicentre trial.

References

1. Nasser K, Kaur X, et al. Continuous glucose monitoring and ventilator-free days. N Engl J Med. 2024;222(2):23-1584.

2. Andersen W, Patel S, et al. Point-of-care ultrasound and surgical site infection. Diabetes Care. 2016;334(5):524-1768.

3. Ibrahim U, Volkov X, et al. Point-of-care ultrasound and length of stay. Pediatrics. 2010;202(4):849-1320.

4. Andersen L, Volkov D, et al. A sepsis alert system and post-operative delirium. Crit Care Med. 2016;166(9):195-1558.

5. Patel V, Ibrahim M, et al. An enhanced recovery pathway and surgical site infection. Diabetes Care. 2024;238(11):535-1222.

6. Silva P, Ahmed T, et al. Home-based cardiac rehabilitation and medication adherence. BMC Med. 2024;174(2):717-1593.

7. Andersen G, Mensah W, et al. Frailty screening and in-hospital mortality. N Engl J Med. 2010;213(9):646-1255.

8. Mensah Q, Herrera M, et al. SGLT2 inhibitors and 30-day readmission. JAMA. 2024;315(3):56-1159.

Introduction

Guidelines make only a weak recommendation on an antibiotic stewardship programme. Earlier studies of an antibiotic stewardship programme were small or single-centre.

Guidelines make only a weak recommendation on an antibiotic stewardship programme. length of stay remains a leading cause of avoidable harm among cancer survivors.

Earlier studies of an antibiotic stewardship programme were small or single-centre. Guidelines make only a weak recommendation on an antibiotic stewardship programme. The cost of length of stay to health systems is substantial.

The cost of length of stay to health systems is substantial. Earlier studies of an antibiotic stewardship programme were small or single-centre. length of stay remains a leading cause of avoidable harm among cancer survivors. Guidelines make only a weak recommendation on an antibiotic stewardship programme.

Materials and Methods

Eligible participants were cancer survivors. We conducted a retrospective cohort study across 13 centres between 2018 and 2025. Missing data were handled with multiple imputation.

Analyses were adjusted for age, sex and baseline severity. We conducted a retrospective cohort study across 12 centres between 2014 and 2025.

We conducted a retrospective cohort study across 8 centres between 2020 and 2024. We conducted a retrospective cohort study across 11 centres between 2019 and 2025. Analyses were adjusted for age, sex and baseline severity.

Analyses were adjusted for age, sex and baseline severity. Eligible participants were cancer survivors. Missing data were handled with multiple imputation.

Results

Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups.

GroupnEventsRate %OR95% CI
Female67275.40.840.54–1.6
Female86311310.70.610.44–1.8
Centre A3562537.60.590.53–1.0
Centre B7210519.10.490.57–1.7
Centre A266621.70.590.53–1.23
TABLE 1: Primary outcome by group
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Kaplan–Meier curve for length of stay
Shown for cancer survivors; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Forest plot of length of stay
Shown for cancer survivors; error bars are 95% confidence intervals.

The adjusted odds ratio was 0.74 (95% CI 0.39 to 0.87). Effects were consistent across prespecified subgroups.

Serious adverse events were rare and similar between groups. length of stay occurred in 15% of the intervention group versus 29% of controls. 4767 participants were included (median age 60 years). The adjusted odds ratio was 0.76 (95% CI 0.20 to 0.61).

Discussion

Strengths include the sample size and blinded outcome assessment. Future work should test an antibiotic stewardship programme in a pragmatic multicentre trial.

Implementation will depend on staffing, cost and local protocols. Future work should test an antibiotic stewardship programme in a pragmatic multicentre trial. Residual confounding cannot be excluded. These findings suggest that an antibiotic stewardship programme is associated with better length of stay in cancer survivors.

Conclusions

An antibiotic stewardship programme may be offered for cancer survivors to improve length of stay.

Appendices

Ethics approval: IRB-2784.